Phase I Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
18 Years
N/A
Both
Metastatic Liver Cancer
Trial Information
Phase I Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
Patients with adequate liver function and performance status in whom liver-directed therapy
and capecitabine would be appropriate are eligible for this clinical trial.
Inclusion Criteria:
- Adequate liver function
- Adequate performance status
Exclusion Criteria:
- Significant extrahepatic disease
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.
Outcome Time Frame:
ongoing
Safety Issue:
Yes
Principal Investigator
Steven J. Cohen, M.D.
Investigator Role:
Study Chair
Investigator Affiliation:
Fox Chase Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
FCCC04043
NCT ID:
NCT00604409
Start Date:
April 2006
Completion Date:
December 2013
Related Keywords:
- Metastatic Liver Cancer
- Liver Neoplasms
Name | Location |
|---|---|
| Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
